| The role of glucagon in the pathophysiology and treatment of type 2 diabetes S Hædersdal, A Lund, FK Knop, T Vilsbøll Mayo Clinic Proceedings 93 (2), 217-239, 2018 | 153 | 2018 |
| Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes NJ Wewer Albrechtsen, AE Junker, M Christensen, S Hædersdal, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 314 (1 …, 2018 | 80 | 2018 |
| Metabolic control analysis of hepatic glycogen synthesis in vivo Y Nozaki, MC Petersen, D Zhang, DF Vatner, RJ Perry, A Abulizi, ... Proceedings of the National Academy of Sciences 117 (14), 8166-8176, 2020 | 65 | 2020 |
| Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers KM Renault, EM Carlsen, S Hædersdal, L Nilas, NJ Secher, ... International journal of obesity 41 (4), 598-605, 2017 | 53 | 2017 |
| Inflammatory markers in the second trimester prior to clinical onset of preeclampsia, intrauterine growth restriction, and spontaneous preterm birth S Haedersdal, JD Salvig, M Aabye, CW Thorball, M Ruhwald, S Ladelund, ... Inflammation 36, 907-913, 2013 | 50 | 2013 |
| Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases S Hædersdal, A Andersen, FK Knop, T Vilsbøll Nature Reviews Endocrinology 19 (6), 321-335, 2023 | 47 | 2023 |
| Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double … AS Christensen, S Hædersdal, J Støy, H Storgaard, U Kampmann, ... Diabetes Care 43 (9), 2025-2033, 2020 | 37 | 2020 |
| GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1α mutation carriers AS Christensen, S Hædersdal, H Storgaard, K Rose, NL Hansen, JJ Holst, ... Diabetes 69 (9), 1989-2002, 2020 | 19 | 2020 |
| Blood chimerism in dizygotic monochorionic twins during 5 years observation MH Dziegiel, MH Hansen, S Haedersdal, AN Barrett, K Rieneck, KM Main, ... American Journal of Transplantation 17 (10), 2728-2732, 2017 | 13 | 2017 |
| The role of glucagon in the acute therapeutic effects of SGLT2 inhibition S Hædersdal, A Lund, E Nielsen-Hannerup, H Maagensen, G van Hall, ... Diabetes 69 (12), 2619-2629, 2020 | 12 | 2020 |
| The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes S Hædersdal, A Lund, H Maagensen, E Nielsen-Hannerup, LS Gasbjerg, ... European journal of endocrinology 186 (2), 207-221, 2022 | 8 | 2022 |
| Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo … AS Christensen, H Storgaard, S Hædersdal, T Hansen, FK Knop, ... BMJ open 8 (10), e022517, 2018 | 7 | 2018 |
| The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes S Hædersdal, A Lund, E Nielsen-Hannerup, H Maagensen, JL Forman, ... European Journal of Endocrinology 187 (4), 507-518, 2022 | 3 | 2022 |
| 1952-P: Glucagon receptor antagonism increases plasma amino acids and glucagon S Haedersdal, NJ WEWER ALBRECHTSEN, AB Lund, KD Galsgaard, ... Diabetes 68 (Supplement_1), 2019 | 3 | 2019 |
| Individual and combined glucose-lowering effects of glucagon receptor antagonism and sodium-glucose cotransporter 2 inhibition S Hædersdal, AB Lund, H Maagensen, E Nielsen-Hannerup, JJ Holst, ... Diabetes 67 (Supplement_1), 2018 | 3 | 2018 |
| 981-P: GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in HNF1A diabetes AS Christensen, S Hædersdal, H Storgaard, K Rose, NL Hansen, JJ Holst, ... Diabetes 68 (Supplement_1), 2019 | 2 | 2019 |
| Diagnosis and treatment of maturity onset diabetes of the young type 3 K Rose, AS Christensen, H Storgaard, S Hædersdal, T Hansen, FK Knop, ... Ugeskrift for Laeger 180 (6), V06170502-V06170502, 2018 | 2 | 2018 |
| Individual and combined glucose-lowering effects of glucagon receptor antagonism and dipeptidyl peptidase-4 inhibition S Haedersdal, AB Lund, E Nielsen-Hannerup, H Maagensen, JJ Holst, ... Diabetes 67 (Supplement_1), 2018 | 1 | 2018 |
| The role of glucagon in gastrointestinal-mediated glucose-disposal and incretin effect in patients with type 2 diabetes and normal glucose tolerant individuals E Nielsen-Hannerup, S Hædersdal, A Lund, HEG Maagensen, JJ Holst, ... 53rd Annual Meeting of the European Association for the study of Diabetes EASD, 2017 | 1 | 2017 |
| Glucagon receptor antagonism lowers fasting glucose but not postprandial glucose excursions in patients with type 2 diabetes S Haedersdal, A Lund, H Maagensen, E Nielsen-Hannerup, JJ Holst, ... Diabetes 66, A532-A532, 2017 | 1 | 2017 |
